6E4F
Crystal structure of ARQ 531 in complex with the kinase domain of BTK
Summary for 6E4F
Entry DOI | 10.2210/pdb6e4f/pdb |
Descriptor | Tyrosine-protein kinase BTK, 1,5-anhydro-2-{[5-(2-chloro-4-phenoxybenzene-1-carbonyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino}-2,3,4-trideoxy-D-erythro-hexitol, IMIDAZOLE, ... (5 entities in total) |
Functional Keywords | inhibitor, complex, signaling protein, signaling protein-inhibitor complex, signaling protein/inhibitor |
Biological source | Homo sapiens (Human) |
Total number of polymer chains | 1 |
Total formula weight | 34494.83 |
Authors | Eathiraj, S. (deposition date: 2018-07-17, release date: 2018-09-05, Last modification date: 2024-03-13) |
Primary citation | Reiff, S.D.,Mantel, R.,Smith, L.L.,Greene, J.T.,Muhowski, E.M.,Fabian, C.A.,Goettl, V.M.,Tran, M.,Harrington, B.K.,Rogers, K.A.,Awan, F.T.,Maddocks, K.,Andritsos, L.,Lehman, A.M.,Sampath, D.,Lapalombella, R.,Eathiraj, S.,Abbadessa, G.,Schwartz, B.,Johnson, A.J.,Byrd, J.C.,Woyach, J.A. The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation. Cancer Discov, 8:1300-1315, 2018 Cited by PubMed: 30093506DOI: 10.1158/2159-8290.CD-17-1409 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (1.15 Å) |
Structure validation
Download full validation report